Volume 2.37 | Oct 1

Immune Regulation News 2.37, October 1, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


New Therapy Boosts Neuroblastoma Two-Year Cure Rate  ShareThis
Using immunotherapy, pediatric oncologists have achieved the first substantial increase in over a decade in cure rates for the childhood cancer neuroblastoma. [Press release from The Children’s Hospital of Philadelphia discussing online prepublication in the New England Journal of Medicine]

Request a Sample  
Fast Isolation of Functional Human Regulatory T Cells
with EasySep®


Interested in recruiting talented individuals? Post your career opportunities in Immune Regulation News at no cost. Contact us at [email protected]


Research on Killer HIV Antibodies Provides Promising New Ideas for Vaccine Design
Researchers have made two fundamental new discoveries about the immune defenses of a rare group of HIV patients whose bodies can naturally keep the virus at bay. [Press release from the Rockerfeller University discussing online prepublication in Nature]

Study Finds Increasing Number of Celiac Cases, Particularly in the Elderly
Working to solve the puzzle of when people develop celiac disease has led researchers to some surprising findings. They have found that the autoimmune disorder is on the rise with evidence of increasing cases in the elderly. [Press release from the University of Maryland Medical Center discussing online prepublication in the Annals of Medicine]

Request A Poster  
Isolate Untouched Cells for
Antigen Processing and Presentation
with EasySep®

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Outcome After Reduced Chemotherapy for Intermediate-Risk Neuroblastoma
A very high rate of survival among patients with intermediate-risk neuroblastoma was achieved with a biologically based treatment assignment involving a substantially reduced duration of chemotherapy and reduced doses of chemotherapeutic agents as compared with the regimens used in earlier trials. [N Engl J Med]

Polyreactivity Increases the Apparent Affinity of Anti-HIV Antibodies by Heteroligation
Here, researchers show that during the human antibody response to HIV, somatic mutations that increase antibody affinity also increase breadth and neutralizing potency. [Nature]

The S1P1-mTOR Axis Directs the Reciprocal Differentiation of TH1 and Treg Cells
Here, researchers found that the differentiation of proinflammatory T helper type 1 cells and anti-inflammatory Foxp3+ regulatory T cells was reciprocally regulated by S1P1, a receptor for the bioactive lipid sphingosine 1-phosphate. [Nat Immunol]

The Cytosolic Exonuclease TREX1 Inhibits the Innate Immune Response to Human Immunodeficiency Virus Type 1
Here, researchers found that the cytosolic exonuclease TREX1 suppressed interferon triggered by HIV. [Nat Immunol]

The Essential Functions of Adipo-Osteogenic Progenitors as the Hematopoietic Stem and Progenitor Cell Niche
A niche composed of adipo-osteogenic progenitors is required for proliferation of hematopoietic stem cells (HSCs) and lymphoid and erythroid progenitors, as well as maintenance of HSCs in an undifferentiated state. [Immunity]

Notch Signaling is a Critical Regulator of Allogeneic CD4+ T Cell Responses Mediating Graft-Versus-Host Disease
Here, researchers reported that Notch signaling is a potent regulator of T cell activation, differentiation and function during acute graft-versus-host disease. [Blood]

Critical Roles for Rac GTPases in T Cell Migration to and Within Lymph Nodes
Previous studies in other cell types had shown that Rac GTPases transduce signals leading to cell migration and adhesion, however their roles in T cells were unknown. Using both 3D intravital and in vitro approaches, researchers show that Rac1- and Rac2-deficient T cells have multiple defects in this recirculation process. [Blood]

TGF-Beta1 Accelerates Dendritic Cell Differentiation from Common Dendritic Cell Progenitors and Directs Subset Specification Toward Conventional Dendritic Cells
In this study, researchers describe a two-step culture system that recapitulates dendritic cell (DC) development from c-kit(hi)Flt3(-/lo) multipotent progenitors into common DC progenitors (cDC) and further into cDC and plasmacytoid DC subsets. [J Immunol]

Th Cells Act Via Two Synergistic Pathways to Promote Antiviral CD8+ T Cell Responses
In this study, researchers unraveled the mechanisms of T cell help for CD8+ T cell responses during vaccinia virus infection. [ J Immunol]

Natural History of Celiac Disease Autoimmunity in a USA Cohort Followed Since 1974
During a 15-year study period, celiac disease prevalence increased two-fold in the CLUE cohort and five-fold overall in the US since 1974. [Ann Med]


Results from Argos Therapeutics’ Immunotherapy Phase II Study for Treatment of Renal Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
Argos Therapeutics announced that results from its Arcelis (TM) immunotherapy Phase II study for the treatment of renal cell carcinoma have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium. [Argos Therapeutics, Inc. Press Release]

Avila Initiates Phase I Clinical Study of AVL-292, a Targeted Covalent Drug and Novel Potential Treatment for B Cell Cancers and Autoimmune Diseases
“Avila Therapeutics (TM), Inc., announced that it has initiated a phase I clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL- 292, a novel, orally available, covalent drug that targets Bruton’s tyrosine kinase. [Avila Therapeutics (TM), Inc. Press Release]

Sanofi Pasteur to Acquire VaxDesign, a U.S. Biotechnology Company
Sanofi Pasteur, announced that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system. [VaxDesign Press Release]

Tolerx Presents Baseline Data from DEFEND-1 Study Demonstrating that More Convenient Fasting C-Peptide Test Yields Comparable Results to Standard Diagnostic Test for Type I Diabetes
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented an analysis of baseline data from the Phase III DEFEND-1 clinical trial of otelixizumab in patients with autoimmune new onset type I diabetes. [Tolerx, Inc. Press Release]

Mining the “Wisdom of Crowds” to Attack Disease
A large, multidisciplinary panel has recently selected 12 pioneering ideas for attacking type I diabetes, ideas selected through a crowdsourcing experiment called the Challenge in which all members of the Harvard community, as well as members of the general public, were invited to answer the question: What do we not know to cure type I diabetes? [Harvard Medical School Press Release]


NIH Grants Will Advance Studies of the Form and Function of Proteins
The National Institutes of Health has awarded 23 grants for structural biology research totaling up to $290 million over five years. [National Institutes of Health, United States]

NCBI Launches the Database of Genomic Structural Variations
The National Institutes of Health announced the launch of a new resource, called the Database of Genomic Structural Variation, or dbVar, to help scientists understand how differences in DNA contribute to human health and disease. [National Institutes of Health, United States]

NIH Releases Biennial Report of the Director
Dr. Francis S. Collins, M.D., Ph.D, director of the National Institutes of Health, announced the release of the Biennial Report of the Director, NIH, for fiscal years 2008 and 2009. The report provides an integrated portrait of NIH research activities, making it easy for Congress, advocates and patient groups and the general public to understand the many activities of the agency. [National Institutes of Health, United States]

The NCI Cancer Immunotherapy Trials Network (CITN) Seeks Member Clinical Sites (NOT-CA-10-034) [National Institutes of Health, United States]

Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR [U43/U44]) (PAR-10-286) [National Institutes of Health, United States]

Office of Biotechnology Activities, Office of Science Policy, Office of the Director; Notice of Meeting (FR Doc. 2010-23947) [National Institutes of Health, United States]

National Center for Research Resources; Notice of Closed Meeting (FR Doc. 2010-23852) [National Institutes of Health, United States]

Center for Scientific Review; Amended Notice of Meeting (FR Doc. 2010-23847) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meeting (FR Doc. 2010-23849) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-23860) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-23952) [National Institutes of Health, United States]

EVENTS (Listed by Date)

Cytokines 2010: Cytokines in Infectious Diseases, Autoimmune Disorders and Cancer
October 3-7, 2010
Chicago, United States

5th International Conference on Gene Regulation in Lymphocyte Development
October 9-14, 2010
Chania, Greece

The 8th Asia Pacific Congress of Allergy, Asthma and Clinical Immunology
November 7-10, 2010

2010 Annual Meeting of the American College of Allergy, Asthma & Immunology
November 11-16, 2010
Phoenix, United States

39th Autumn Immunology Conference
November 19-22, 2010
Chicago, United States

Cell Symposia: Influenza – Translating Basic Insights
December 2-4, 2010
Washington, D.C., United States

The 50th Midwinter Conference of Immunologists at Asilomar
January 22-25, 2011
Pacific Grove, United States

Phacilitate 7th Annual Cell & Gene Therapy Forum 2011
January 24-26, 2011
Washington, DC, United States

Phacilitate 9th Annual North American Vaccine Forum
January 24-26, 2011
Washington, DC, United States

Keystone Symposia: Dendritic Cells and the Initiation of Adaptive Immunity joint with Cancer Control by Tumor Suppressors and Immune Effectors
February 12-17, 2011
Santa Fe, United States

Keystone Symposia: Genetics, Immunology and Repair in Multiple Sclerosis
February 15-20, 2011
Taos, United States

BMT Tandem Meetings (ASBMT/CIBMTR)
February 17-21, 2011
Honolulu, Hawaii

18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
February 27-March 2, 2011
Boston, United States

The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics
March 16-19, 2011
Las Vegas, United States

2011 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting
March 18-22, 2011
San Francisco, United States

Microbiota and Mucosal Immunology: The Interface in Health and Disease
April 14-16, 2011
San Francisco, United States

GTCbio: 2nd International Conference on Cancer Immunotherapy & Immunomonitoring
May 2-5, 2011
Budapest, Hungary

American Society of Gene and Cell Therapy (ASGCT) 14th Annual Meeting
May 18-22, 2011
Seattle, United States

Gordon Research Conference: Viruses & Cells
May 29-June 3, 2011
Lucca (Barga), Italy

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Cell Therapy Technologist (Opexa Therapeutics)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

Visit here to post your career opportunities.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Immune Regulation News: Archives  |  Events  |  Subscribe  |  Contact Us